Matter Bio Initiates First-in-Human Clinical Trial of Novel Immunotherapy for Advanced Pancreatic Cancer
PR Newswire
SAN FRANCISCO, Nov. 18, 2026
Phase 1 study evaluating Lm-LLO-TT, a novel Listeria-based immunotherapy designed to harness existing immune memory against cancer, is now recruiting patients.
SAN FRANCISCO, Nov. 18, 2026 /PRNewswire-PRWeb/ -- Matter Bio, a biotechnology company developing innovative therapies targeting the underlying biology of disease, today announced the initiation of its first-in-human Phase 1 clinical trial of Lm-LLO-TT in patients with unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC).
The clinical trial (NCT07828236) is now recruiting patients at Montefiore Medical Center in New York. The study marks an important milestone for Matter Bio and its subsidiary Loki Therapeutics as it advances its novel immunotherapy platform into clinical development.
Pancreatic cancer remains one of the most difficult cancers to treat, particularly in patients whose disease cannot be surgically removed. Despite advances in treatment, patients with advanced disease continue to face limited therapeutic options.
Lm-LLO-TT takes a different approach to cancer immunotherapy. The investigational therapy uses an attenuated strain of Listeria monocytogenes engineered to express a tetanus toxoid antigen. By leveraging the body's existing immune memory against tetanus, the therapy is designed to activate T cells and redirect immune responses toward tumors.
"Reaching the clinic is an important milestone for our team and for everyone who has contributed to developing this therapy," said Christopher Bradley, CEO of Matter Bio. "Pancreatic cancer remains incredibly challenging to treat, and we believe this approach offers a promising new avenue worth exploring. We are excited to begin evaluating Lm-LLO-TT in patients."
The open-label, dose-escalation Phase 1 study will evaluate the safety, tolerability, and appropriate dosing of Lm-LLO-TT administered intraperitoneally in combination with low-dose gemcitabine. The study plans to enroll up to 18 patients with previously treated unresectable or metastatic PDAC and will also assess preliminary anti-tumor activity and immune responses.
"Our approach is based on a simple idea: rather than teaching the immune system something entirely new, we want to harness the strong immune memory that patients already have against tetanus and redirect it toward cancer," said Sam Sharifi, PhD, Chief Scientific Officer of Matter Bio. "After years of preclinical development, we are excited to bring this approach into the clinic. This trial is an important first step toward understanding its potential for patients with pancreatic cancer."
Clinical Trial: The trial is registered on ClinicalTrials.gov under identifier NCT07828236. https://clinicaltrials.gov/study/NCT07828236
About Matter Bio
Matter Bio is a biotechnology company developing technologies and therapeutics to address fundamental drivers of disease, with a focus on genomic integrity and cancer. By combining advances in molecular biology, genomics, and immunotherapy, Matter Bio aims to develop innovative approaches to treating complex diseases and improving human health.
For more information, visit www.matter.bio.
Forward-Looking Statements
This press release contains forward-looking statements regarding the clinical development of Lm-LLO-TT, including the conduct of the Phase 1 trial, potential therapeutic benefits, and future development plans. These statements involve risks and uncertainties, and actual results may differ materially from current expectations. Lm-LLO-TT is investigational and has not been approved by the FDA or any other regulatory authority.
Media Contact: media@matterbio.com
Media Contact
Media Team, Matter Bio, 1 8087813434, media@matterbio.com, http://www.matter.bio
View original content to download multimedia:https://www.prweb.com/releases/matter-bio-initiates-first-in-human-clinical-trial-of-novel-immunotherapy-for-advanced-pancreatic-cancer-302944365.html
SOURCE Matter Bio
